An observational study in Autoimmune Encephalitis, Anti-NMDAR Encephalitis and Anti-GABABR Encephalitis, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Not yet recruiting at 5 sites in China. Open to participants aged 14 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Autoimmune Diseases of the Nervous System with a site in China — 18 open to participants now, 20 under way, 3 of them phase 3. Autoimmune Diseases of the Nervous System · China.
Among the 26 studies in Autoimmune Diseases of the Nervous System with a site in China, this one is the 6th largest by planned enrollment of the 13 observational ones that give a count, is one of 5 that started in 2026, is one of 13 observational ones, reaches primary completion later than 14 of the 19 other live ones, and was the 26th registered.
123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.
Browse Autoimmune Diseases of the Nervous System studies →18 of the 26 studies in Autoimmune Diseases of the Nervous System with a site in China are open now. Recruiting first, the newest first:
Beijing Tongren Hospital · Sites in China
Ages 18+
Tongji Hospital · Sites in China
Ages 18–75
Tongji Hospital · Sites in China
Ages 18–70
Tianjin Huanhu Hospital · Sites in China
Ages 18+
Tongji Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.
This study: 14 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 160 across 57 observational studies indexed under Autoimmune Diseases of the Nervous System.
Median enrollment 36 across the 13 interventional studies, 300 across the 13 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 26 have an industry lead sponsor. The 10 most frequent:
Third Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 134 studies on the registry; 35 are open to participants now.
Third Affiliated Hospital, Sun Yat-Sen University has 2 studies filed under Autoimmune Diseases of the Nervous System — fewer than ten, so there is no comparison to draw.
6 of the studies in Autoimmune Diseases of the Nervous System with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05503264Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | 2026-12-16 |
| NCT07337785Tongji HospitalCD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | 2026-12-01 |
| NCT06388161Shen Chun-HongNeural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology | 2026-12-31 |
| NCT06797024Tongji HospitalJY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders | 2026-12-31 |
| NCT04561557Tongji HospitalSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | 2027-02-22 |
Add all 6 to your calendar (.ics) → With an account.
Among the 26 studies in Autoimmune Diseases of the Nervous System with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, blinded, cross-sectional study aims to evaluate the clinical performance of a novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABAB receptor (anti-GABABR) antibodies. A total of 300 participants will be enrolled across four groups: (a) 50 patients with anti-GABABR antibody-positive encephalitis; (b) 100 patients with suspected autoimmune encephalitis and negative anti-neuronal antibody cell-based assay (CBA); (c) 50 patients with non-autoimmune disease (Alzheimer's disease); and (d) 100 patients with anti-NMDAR antibody-positive encephalitis. Residual serum and cerebrospinal fluid samples will be tested using the optimized DAB-TBA. Discordant results between CBA and DAB-TBA will be adjudicated by an independent panel using confirmatory methods (immunoblot, repeat CBA, and clinical follow-up), and inter-reader agreement will be reported. The sensitivity, specificity, and ROC curve of the assay will be evaluated against the reference standard.
Anti-GABAB receptor (anti-GABABR) encephalitis is a recognized subtype of autoimmune encephalitis. Antibody detection is essential for diagnosis and differential diagnosis, and cell-based assays (CBA) are the current recommended reference method. The tissue-based assay (TBA) using DAB chromogenic immunohistochemistry offers a widely accessible complement for detecting anti-neuronal antibodies. This study validates the clinical performance of a novel DAB chromogenic TBA developed by Guangzhou KingMed Diagnostics Center. Participants are recruited from neurology departments across multiple centers and enrolled into four groups based on clinical diagnosis and CBA results. Residual serum and CSF samples (no additional sampling) are tested in a blinded manner, and the sensitivity, specificity, and ROC curve of the DAB-TBA for detecting anti-GABABR antibodies are evaluated against the reference standard.
Patients aged 14-85 years recruited from neurology departments across participating centers, grouped as: (a) anti-GABABR antibody-positive encephalitis; (b) suspected autoimmune encephalitis with negative anti-neuronal antibody CBA; (c) non-autoimmune disease (Alzheimer's disease); (d) anti-NMDAR antibody-positive encephalitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group a: age 14-85 years; anti-GABABR antibody CBA positive; diagnosed with GABABR antibody encephalitis. Group b: age 14-85 years; suspected encephalitis with acute/subacute onset (\<3 months) and one or more neurological/psychiatric symptoms (e.g. memory impairment, seizures, psychiatric/behavioral abnormalities); anti-neuronal antibody CBA negative; other etiologies reasonably excluded; identifiable address and resident in the region during treatment; willing to provide and comply with follow-up. Group c: age 14-85 years; non-autoimmune disease patients (Alzheimer's disease confirmed by serum/CSF AD biomarker testing). Group d: age 14-85 years; anti-NMDAR antibody CBA positive; diagnosed with NMDAR antibody encephalitis.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-GABABR antibody-positive encephalitis group (n=50)
Suspected AE with negative anti-neuronal antibody CBA (n=100)
Non-autoimmune disease group: Alzheimer's disease (n=50)
Anti-NMDAR antibody-positive encephalitis group (n=100)
Sensitivity of novel DAB chromogenic TBA for detection of anti-GABABR antibodies
Sensitivity of the novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABABR antibodies, calculated as true positive / (true positive + false negative), using CBA results as the reference standard.
Time frame: up to 3 months
Specificity of the novel DAB chromogenic TBA for detection of anti-GABABR antibodies
Specificity of the novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABABR antibodies, calculated as true negative / (true negative + false positive), using CBA results as the reference standard.
Time frame: up to 3 months
Area under the ROC curve (AUC) of DAB chromogenic TBA for anti-GABABR antibody detection
ROC curve and AUC value of the novel DAB chromogenic TBA for anti-GABABR antibody detection with CBA as reference standard.
Time frame: up to 3 months
Cohen's kappa coefficient between DAB-TBA and CBA reference method
Concordance between the novel DAB chromogenic TBA and the CBA reference method for anti-GABABR antibody detection, quantified by Cohen's kappa coefficient.
Time frame: up to 3 months
Agreement between serum and CSF detection results by DAB-TBA
Concordance of DAB chromogenic TBA results between paired serum and CSF samples, expressed as agreement percentage and Cohen's kappa.
Time frame: up to 3 months
Subgroup detection performance of DAB-TBA
Sensitivity and specificity of the DAB chromogenic TBA stratified by the four predefined subgroups (anti-GABABR-positive encephalitis, CBA-negative suspected autoimmune encephalitis, non-autoimmune neurological disease, and anti-NMDAR encephalitis).
Time frame: up to 3 months
Plan to share: No — Individual participant data will not be shared. Aggregated study results will be published in peer-reviewed scientific journals.
Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Autoimmune Diseases of the Nervous System →
Third Affiliated Hospital, Sun Yat-Sen University →